Posted by Michael Wonder on 08 Jan 2019
CDER’s work to ensure drug safety is an ongoing top priority
8 January 2019 - Yesterday, I reflected on the FDA’s Center for Drug Evaluation and Research’s wide array of new drug therapy approvals in 2018.
Today, I’d like to discuss the work we do to make sure the drugs we approve are not only effective, but safe. Safety is a priority both before and after approval and maintaining the safety of drugs that Americans rely on is a complex undertaking because new safety issues can arise at any time—regardless of how long a drug has been in use or its past record of safety.
In 2018, we faced one of those challenges.
